Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

View Full Paper
Ask AI
Bookmark
Share

Authors

OCOnyee ChanDSDavid A. SallmanLPLia Perez

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved overall survival with allogeneic HCT compared to hypomethylating agent/venetoclax in elderly AML patients, suggesting HCT is preferable.

Key Points

  • HCT provides better overall survival than hypomethylating agent therapy in elderly patients with AML.
  • In patients achieving CR or CRi, HCT significantly reduced 3-year relapse rates compared to HMA/VEN.
  • Analysis utilized log-rank test for survival estimates and evaluated comorbidity using specific indices.
  • Findings highlight critical treatment decisions, emphasizing the need for HCT in clinically suitable elderly AML cases.

Cite This Study

Chan et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d617https://doi.org/10.1182/blood-2025-4300
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  2. 2Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party2025
  3. 3Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database2025
  4. 4Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  5. 5Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025